Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引：0

作者：

Koper, Agnieszka ^{[1
,2
]}

Wilenski, Slawomir ^{[3
,4
]}

Sledzinska, Paulina ^{[5
]}

Bebyn, Marek ^{[5
]}

Koper, Krzysztof ^{[2
,6
]}

机构：

[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland

[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland

[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland

[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland

[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland

[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 12期

关键词：

Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;

D O I：

10.1007/s00432-023-04909-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y

引用

页码：10867 / 10877

页数：11

共 28 条

[1] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status [J].

Carriles, C. ;

Jimenez-Fonseca, P. ;

Sanchez-Canovas, M. ;

Pimentel, P. ;

Carmona-Bayonas, A. ;

Garcia, T. ;

Carbajales-Alvarez, M. ;

Lozano-Blazquez, A. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (12) :1781-1785

[2] Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J].

Cervantes, A. ;

Adam, R. ;

Rosello, S. ;

Arnold, D. ;

Normanno, N. ;

Taieb, J. ;

Seligmann, J. ;

De Baere, T. ;

Osterlund, P. ;

Yoshino, T. ;

Martinelli, E. .

ANNALS OF ONCOLOGY, 2023, 34 (01) :10-32

[3] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].

Di Nicolantonio, Federica ;

Martini, Miriam ;

Molinari, Francesca ;

Sartore-Bianchi, Andrea ;

Arena, Sabrina ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Mazzucchelli, Luca ;

Frattini, Milo ;

Siena, Salvatore ;

Bardelli, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712

[4] Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer [J].

Diblasio, CJ ;

Kattan, MW .

UROLOGY, 2003, 62 (6B) :9-18

[5] Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours [J].

Doi, T. ;

Ohtsu, A. ;

Yoshino, T. ;

Boku, N. ;

Onozawa, Y. ;

Fukutomi, A. ;

Hironaka, S. ;

Koizumi, W. ;

Sasaki, T. .

BRITISH JOURNAL OF CANCER, 2012, 107 (03) :429-434

[6] Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data [J].

Fernandez Montes, Ana ;

Carmona-Bayonas, Alberto ;

Jimenez-Fonseca, Paula ;

Vazquez Rivera, Francisca ;

Martinez Lago, Nieves ;

Covela Rua, Marta ;

Cousillas Castineiras, Antia ;

Gonzalez Villarroel, Paula ;

De la Camara Gomez, Juan ;

Carlos Mendez Mendez, Jose ;

Carriles Fernandez, Carmen ;

Sanchez Canovas, Manuel ;

Garcia Garcia, Teresa .

SCIENTIFIC REPORTS, 2021, 11 (01)

[7] Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides [J].

Fukushima, M ;

Suzuki, N ;

Emura, T ;

Yano, S ;

Kazuno, H ;

Tada, Y ;

Yamada, Y ;

Asao, T .

BIOCHEMICAL PHARMACOLOGY, 2000, 59 (10) :1227-1236

[8] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].

Heinemann, Volker ;

von Weikersthal, Ludwig Fischer ;

Decker, Thomas ;

Kiani, Alexander ;

Vehling-Kaiser, Ursula ;

Al-Batran, Salah-Eddin ;

Heintges, Tobias ;

Lerchenmueller, Christian ;

Kahl, Christoph ;

Seipelt, Gernot ;

Kullmann, Frank ;

Stauch, Martina ;

Scheithauer, Werner ;

Hielscher, Joerg ;

Scholz, Michael ;

Mueller, Sebastian ;

Link, Hartmut ;

Niederle, Norbert ;

Rost, Andreas ;

Hoeffkes, Heinz-Gert ;

Moehler, Markus ;

Lindig, Reinhard U. ;

Modest, Dominik P. ;

Rossius, Lisa ;

Kirchner, Thomas ;

Jung, Andreas ;

Stintzing, Sebastian .

LANCET ONCOLOGY, 2014, 15 (10) :1065-1075

[9] How to build and interpret a nomogram for cancer prognosis [J].

Iasonos, Alexia ;

Schrag, Deborah ;

Raj, Ganesh V. ;

Panageas, Katherine S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1364-1370

[10] Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study [J].

Kasi, Pashtoon M. ;

Kotani, Daisuke ;

Cecchini, Michael ;

Shitara, Kohei ;

Ohtsu, Atsushi ;

Ramanathan, Ramesh K. ;

Hochster, Howard S. ;

Grothey, Axel ;

Yoshino, Takayuki .

BMC CANCER, 2016, 16

← 1 2 3 →